The administration of the HE in high doses of 1 mg/L and 3 mg/L resulted in a significant decrease (p < 0.0001) in the specific activity of AChE in a dose-dependent manner compared to the group treated with SCOP. The gene discussed is ACHE; the disease is hereditary elliptocytosis.